Movatterモバイル変換

[0]ホーム

Jump to content

Reviparin sodium

Edit links

From Wikipedia, the free encyclopedia

Pharmaceutical drug

Pharmaceutical compound

Reviparin sodium
Clinical data

AHFS/Drugs.com	International Drug Names
ATC code	B01AB08 (WHO)
Identifiers
CAS Number	9005-49-6^N
DrugBank	DB09259^Y
ChemSpider	none
UNII	5R0L1D739E
KEGG	D03337^N
CompTox Dashboard(EPA)	DTXSID301010914
ECHA InfoCard	100.110.590
^NY (what is this?) (verify)

Reviparin is anantithrombotic and belongs to the group oflow molecular weight heparins (LMWH).

Medical uses

[edit]

Prevention of blood clots
Prophylaxis of perioperativethromboembolism^[1]^[2]
Treatment of DVT with or withoutpulmonary embolism (PE)^[3]
Prophylaxis of acute thrombotic events afterpercutaneous transluminal coronary angioplasty (PTCA)^[4]^[5]

Chemistry

[edit]

Reviparin is a low molecular weight heparin obtained bynitrous acid depolymerization of heparin extracted from porcine intestinal mucosa. Its structure is characterized, for the most part, by a group of 2-O-sulfo-α-lidopyranosuronic acid. The average molecular weight is about 3900daltons.

References

[edit]

^Kakkar VV, Cohen AT, Mohamed MS (1996). "Patients at risk of venous thromboembolism--clinical results with reviparin".Thromb. Res.81 (2 Suppl): S39–45.doi:10.1016/0049-3848(95)00228-6.PMID 8822126.
^Lassen MR, Backs S, Borris LC, Kaltoft-Sørenson M, Coff-Ganes H, Jeppesen E (1999). "Deep-vein thrombosis prophylaxis in orthopedic surgery: hip surgery".Semin. Thromb. Hemost. 25 Suppl 3:79–82.PMID 10549720.
^Gore M, Kelkar P, Rege N, Ross C (October 2004). "Reviparin sodium clivarine: a review of its therapeutic use".J Indian Med Assoc.102 (10):589–90, 592.PMID 15887830.
^Preisack MB, Karsch KR (December 1993). "Experimental and early clinical experience with reviparin-sodium for prevention of restenosis after percutaneous transluminal coronary angioplasty".Blood Coagul. Fibrinolysis. 4 Suppl 1: S55–8, discussion S59–60.PMID 8180331.
^Karsch KR, Preisack MB, Baildon R, Eschenfelder V, Foley D, Garcia EJ, Kaltenbach M, Meisner C, Selbmann HK, Serruys PW, Shiu MF, Sujatta M, Bonan R (November 1996)."Low molecular weight heparin (reviparin) in percutaneous transluminal coronary angioplasty. Results of a randomized, double-blind, unfractionated heparin and placebo-controlled, multicenter trial (REDUCE trial). Reduction of Restenosis After PTCA, Early Administration of Reviparin in a Double-Blind Unfractionated Heparin and Placebo-Controlled Evaluation".J. Am. Coll. Cardiol.28 (6):1437–43.doi:10.1016/s0735-1097(96)00343-9.hdl:1765/55740.PMID 8917255.

External links

[edit]

reviparin at the U.S. National Library of MedicineMedical Subject Headings (MeSH)
Yusuf S, Mehta SR, Xie C, et al. (2005)."Effects of reviparin, a low-molecular-weight heparin, on mortality, reinfarction, and strokes in patients with acute myocardial infarction presenting with ST-segment elevation".JAMA.293 (4):427–35.doi:10.1001/jama.293.4.427.PMID 15671427.

Antithrombotics (thrombolytics,anticoagulants andantiplatelet drugs) (B01)

Antiplatelet drugs

Glycoprotein IIb/IIIa inhibitors	Abciximab Eptifibatide Orbofiban Roxifiban Sibrafiban^§ Tirofiban
ADP receptor/P2Y₁₂ inhibitors	Thienopyridines Clopidogrel Prasugrel Ticlopidine Nucleotide/nucleoside analogs Cangrelor Elinogrel Ticagrelor
Prostaglandin analogue (PGI2)	Beraprost Iloprost Prostacyclin Treprostinil
COX inhibitors	Acetylsalicylic acid/Aspirin^# Aloxiprin Carbasalate calcium Indobufen Triflusal
Thromboxane inhibitors	Thromboxane synthase inhibitors Dipyridamole (+ aspirin) Picotamide Terbogrel Receptor antagonists Terbogrel Terutroban^§
Phosphodiesterase inhibitors	Cilostazol Dipyridamole Triflusal
Other	Cloricromen Ditazole Vorapaxar

Anticoagulants

Vitamin K antagonists
(inhibitII,VII,IX,X)

Factor Xa inhibitors
(with some II inhibition)

Heparin group/ glycosaminoglycans/ (bindantithrombin)	Low-molecular-weight heparin Bemiparin Certoparin Dalteparin Enoxaparin Nadroparin Parnaparin Reviparin Tinzaparin Oligosaccharides Fondaparinux Idraparinux^§ Heparinoids Danaparoid Dermatan sulfate Sulodexide
Direct Xa inhibitors ("xabans")	Apixaban Betrixaban Darexaban^§ Edoxaban Otamixaban^§ Rivaroxaban

Direct thrombin (IIa) inhibitors

Bivalent:Hirudin
- Bivalirudin
- Desirudin
- Lepirudin^‡
Univalent:Argatroban
Dabigatran
Efegatran
Inogatran^§
Melagatran^‡
Ximelagatran^‡

Other

Thrombolytic drugs/
fibrinolytics

Plasminogen activators:r-tPA
- Alteplase^#
- Reteplase
- Tenecteplase
- Desmoteplase^†
UPA
- Saruplase
- Urokinase
Anistreplase
Monteplase
Streptokinase^#
Otherserine endopeptidases:Ancrod^‡
Brinase
Fibrinolysin

Non-medicinal

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

Thisdrug article relating to theblood andblood forming organs is astub. You can help Wikipedia byexpanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Reviparin_sodium&oldid=1136360924"

Categories:

Hidden categories:

[8]ページ先頭